Review the current valuation for Akero Therapeutics Inc (AKRO:XNAS) stock based on a yearly calendar providing PE ratios, cash flow, EBITDA and other company valuation information.

The VC is funded mainly via Rigmora Biotech Investor One and Rigmora Biotech Investor Two, according to a June 27 press release. Both funds are part of Rigmora Holdings, a family office that manages ...

A drug developed by US biotech Akero Therapeutics has hit the mark in a phase 2b trial in non-alcoholic steatohepatitis (NASH) – catapulting it to the forefront of efforts to find effective ...

Find the latest Akero Therapeutics, Inc. (AKRO) stock quote, history, news and other vital information to help you with your stock trading and investing.

Interactive Chart for Akero Therapeutics, Inc. (AKRO), analyze all the data with a huge range of indicators.

Akero Therapeutics, Inc. OverviewBiotechnology / Healthcare Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The ...

Akero Therapeutics announces pricing of stock offering to raise $319M SA NewsWed, Mar. 06, 2024 1 Comment ...

Gyre Therapeutics has a unique business model for evaluating and commercializing drugs in China. Find out why GYRE stock is a ...

Around this time last year, Akero was riding high on positive phase 2b data for its candidate non-alcoholic steatohepatitis (NASH) therapy, but new data has dented optimism about ...